Quote:
Originally Posted by "W"
Well tell your Finance Guy that when I cash it in at 6-7 dollars a share ......He should read up a little more.... 
for any of 3-4 indications OXGN already has positive results. Oncology IS the only niche where GENERICS can not compete. As such.. Big Pharma needs OXGN pipeline.. badly.
All of this against only 9.45M shares.
Do the math |
i hope you make some $$ just sayin im not jumpin on it